1. In Vivo
  2. >>Archive

Are Late-Stage Deals Driving Up the Cost of Preclinical Deals?

With patent expirations looming, and Big Pharma pipelines unable to fill the gap, competition for late-stage licensing opportunities continues to drive late stage-deal valuations ever higher. But is this activity effectively pricing some licensors out of range, sending them instead to earlier-stage deals, and driving up prices there accordingly?

With patent expirations looming, and Big Pharma pipelines unable to fill the gap, competition for late-stage licensing opportunities continues to drive late stage-deal valuations ever higher. But is this activity effectively pricing some licensors out of range, sending them instead to earlier-stage deals, and driving up prices there accordingly? In the chart below, we've broken out average values of preclinical deals versus late-stage deals (Phase II and III) over the past five years. As late stage values have shot up to the $90+ million range on average since 2000, the average preclinical values since then have risen steadily, from $23 million to $44 million, while deal activity has remained relatively constant (78 preclinical deals in 2000, 82 in 2001, and 74 so far in 2002).

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Archive

Final Chance To Have Your Say: Take Our Reader Survey This Week

 
• By Eleanor Malone

Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.

Early Development Deals: Ipsen's Strategy For Biomarker-Driven Success

 
• By Eliza Slawther

Mary Jane Hinrichs, Ipsen’s head of early development, talks to In Vivo about getting ahead of the competition by securing deals for candidates before they enter Phase I trials.   

Shape Our Content: Take The Reader Survey

 
• By Eleanor Malone

Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in the coverage topics, content format or the method in which you receive and access In Vivo, or if you love it how it is, now is the time to have your voice heard.

In Partnership with Cerba Research

Prioritizing Safety in CAR-T Therapy: Patient Monitoring with Cerba Research’s Testing Portfolio

The cell and gene therapy (CGT) clinical trial landscape in general and CAR-T cell clinical trials in particular are a special focus for the FDA, EMA, and other regulatory agencies. The whole industry is thus aware of the recent FDA safety investigation and requirements for labeling CAR therapy products.

More from In Vivo

UK Must Put Adoption On A Par With Innovation, AZ Tells BioWales Forum

 
• By Ashley Yeo

Market access concerns dominated at the annual BioWales In London event, where AstraZeneca set out industry’s priorities and the UK Office for Life Sciences struck an optimistic tone about how the UK will lastingly improve uptake of innovation.

Rising Leaders 2025: Kevin Parker On Climbing Toward Breakthroughs In Biotech

 
• By Meredith Landry

Kevin Parker leads Cartography Biosciences in developing precision therapies for underserved cancer types, targeting proteins exclusive to tumor cells.

Deals In Depth: March 2025

 
• By Maureen Riordan

Eight $1bn+ alliances were penned in March, and five exceeded $2bn.